Thank you for standing by. I would like to welcome you to the Relmada Therapeutics, Inc. annual meeting. I would now like to turn the conference over to Sergio Traversa, CEO. Please go ahead. Good morning, everyone. Welcome to our virtual 2026 annual meeting of stockholders of Relmada Therapeutics, Inc. I'm Sergio Traversa, Chief Executive Officer of Relmada, and it is my pleasure to welcome all of you. It is 9:30 A.M., and in accordance with the notice of the meeting, I will call to order the annual meeting of stockholders of Relmada Therapeutics. After the formal meeting has ended, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to one question. Based on information received from Shandi Jackson, our Inspector of Election, 63.5% in voting power of the shares of the corporation entitled to vote at the meeting are present in person or represented by proxy. I hereby declare a quorum present at the meeting. On behalf of the Board of Directors of the company, I would like to express my appreciation to all stockholders who returned their proxies. Now, I will present the matters to be voted upon. Please note that we will give stockholders an opportunity to comment on the proposals themselves after all proposals have been presented. Proposal number one, election of directors. The first matter to be acted upon by the stockholders is the election of Charles J. Casamento and Sergio Traversa as Class II directors, each to serve for a three-year term that expires at the annual meeting of stockholders in 2029 or until his successor is elected and qualified, or until his earlier resignation or removal. Number two, ratification of appointment of auditors. The second matter being submitted to stockholders for action is to ratify the appointment of CBIZ CPAs, P.C. as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. Number three, approve an amendment to the Relmada 2021 Equity Incentive Plan. The third matter being submitted to stockholders for action is to approve an amendment to the Relmada Therapeutics, Inc. 2021 Equity Incentive Plan to increase the shares of our common stock available for issuance thereunder by 3 million shares. The 2021 plan is to, A, enable the company to attract and retain the types of employees, directors, and consultants who will contribute to the company's long-term success. B, provide incentives that align the interests of employees, consultants, and directors with those of the shareholders of the company. C, promote the success of the company business, thus enhancing the value of the company for the benefit of its stockholders. Number four, approve an amendment to our articles of incorporation. The fourth matter being submitted to stockholders for action is to approve an amendment to our articles of incorporation, as amended, to increase the number of authorized shares of common stock from 150 million to 200 million. If any stockholder would like to make a comment regarding any of the proposals, please submit your comments through the web portal. I don't see any comments, so I move forward. Balloting results. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. Now that everyone has had the opportunity to vote, I now declare the polls for the 2026 Annual Stockholder Meeting closed. Ms. Jackson, do you have preliminary voting results? We do. We've completed a preliminary count of the ballots. For Proposal One, Charles Casamento and Sergio Traversa have received the votes representing a plurality of the votes cast at the meeting to serve as Class II directors. For Proposal Two, a majority of the votes cast have been voted for the appointment by the Board of Directors of CBIZ CPAs, P.C. as the independent registered public accounting firm of the company for the year ending December 31st, 2026. Proposal Three, an amendment to the Equity Incentive Plan, was approved. Proposal Four, an amendment to the articles of incorporation, was approved. Thank you, Ms. Jackson. I will now provide a few short remarks about the company. 2025 marked a transformational year for Relmada Therapeutics. Following the disappointing interim analysis of our former lead program in late 2024, management and the board acted decisively to stabilize the company, preserve cash resources, and undertake a comprehensive strategic review focused on maximizing shareholder value. Through disciplined expense management and careful prioritization, we extended our operating runway while evaluating strategic alternatives with the support of multiple investment banking firms. Ultimately, we concluded that Relmada greatest asset was its experienced clinical development organization and its ability to leverage public market success to acquire and advance clinically de-risked programs with meaningful long-term potential. Executing on this strategy, we successfully acquired two promising clinical-stage assets in 2025. NDV-01 for non-muscle invasive bladder cancer, and sepranolone for Prader-Willi syndrome and potentially other indications. These acquisitions, particularly NDV-01, drove a significant resurgence in shareholder value. With our share price recovering from a low of $0.24 in March 2025 to a post-financing high of $4.83 in December. Increasing market capitalization for approximately $7 million to approximately $353 million at the end of 2025. Equally important, we retained our team during an extraordinarily challenging period, while proactive investor engagement and meaningful insider share purchases helped restore market confidence and position Relmada for future growth. As of March 31st, 2026, we reported $234 million in cash equivalents and short-term investments. As of yesterday close, May 26th, 2026, our market capitalization was in excess of $750 million. In summary, we have taken decisive action to strengthen Relmada for the future. With a diversified pipeline, disciplined strategy, and a laser focus on delivering innovation where it's needed most, we are positioned for meaningful progress in 2026 and beyond. We remain deeply grateful for your trust, your belief in our mission, and your partnership as we move forward. Thank you. Now we would like to open things up for stockholder questions and comments. We give a couple of minutes if there is any question. Well, at this moment, I don't see any question. If there is no other business, this ends our meeting. I would like again to express my sincere appreciation to the stockholders who attended the meeting and voted, as well as those who submitted their proxies but were not able to be present. The meeting is now adjourned. Thank you. You may now disconnect. Everyone have a great day. Thank you all for joining.